Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Asymptomatic Pembrolizumab-Associated Hypertriglyceridemia.

Cureus·2026

Same author

Current and emerging therapies targeting cell surface antigens and epigenetics in extensive stage small cell lung cancer: primer for clinicians.

Therapeutic advances in medical oncology·2026

Same author

EZH1/2 inhibition improves immunotherapy response through MHC Class II de-repression and neutrophil reprogramming.

bioRxiv : the preprint server for biology·2026

Same author

Timing of insertable cardiac monitor implantation after embolic stroke of undetermined source and its impact on atrial fibrillation detection: A target trial emulation analysis.

International journal of stroke : official journal of the International Stroke Society·2026

Same author

Mental Health Needs of Families of Patients in Intensive Care Units and the Role of Mobile Health: Survey Study.

JMIR formative research·2026

Same author

Atrial fibrillation detection after embolic stroke of undetermined source: Development and validation of the CATCH-AF score.

International journal of stroke : official journal of the International Stroke Society·2026

Search research articles

Related Experiment Video

Updated: Jun 3, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

New developments in immunotherapy for SCLC.

Tsering Dolkar¹, Christopher Gates², Zhonglin Hao³

¹Hospital Medicine, University of Kentucky, Lexington, Kentucky, USA.

Journal for Immunotherapy of Cancer

|January 6, 2025

Summary

Small cell lung cancer (SCLC) shows initial treatment response but relapses quickly. Emerging immunotherapies targeting DLL3, like bispecific T cell engagers and CAR-T cells, offer new hope for patients with this aggressive neuroendocrine neoplasm.

Keywords:

Bispecific T cell engager - BiTE Immunotherapy Lung Cancer

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Related Experiment Videos

Last Updated: Jun 3, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Area of Science:

Oncology
Immunotherapy
Neuroendocrine Neoplasms

Background:

Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer characterized by initial treatment sensitivity followed by rapid relapse and therapeutic resistance.
While genetic mutations are rare in SCLC, the DLL3 receptor is highly expressed, presenting a promising target for novel therapies.

Purpose of the Study:

To review emerging immunotherapeutic strategies for small cell lung cancer targeting the DLL3 receptor.
To highlight the potential of bispecific T cell engagers, CAR-T cells, and antibody-drug conjugates in overcoming SCLC treatment refractoriness.

Main Methods:

Review of current clinical trial data for DLL3-targeted immunotherapies in SCLC.
Analysis of early phase II and phase III trial results for bispecific T cell engagers.
Overview of ongoing first-in-human CAR-T cell trials for SCLC.

Main Results:

Bispecific T cell engagers targeting DLL3 have demonstrated promising outcomes in ongoing phase II and III clinical trials.
Early clinical investigations into CAR-T cell therapies for SCLC are currently in progress.

Conclusions:

DLL3-targeted immunotherapies represent a significant advancement in SCLC treatment, offering potential for improved patient outcomes.
The development of bispecific T cell engagers and CAR-T cells shows considerable promise for managing this challenging malignancy.